華泰金融(HK)：給予康諾亞-B(02162.HK)“買入”評級 目標價58.76港元

2024-09-18 18:31:08 來源： 同花順金融研究中心

　　華泰金融(HK)9月15日發布公告。On September 11, stapokibart was approved by the NMPA for moderate-to-severe AD in adults, becoming the first domestic anti-IL-4RαmAb approved (second globally). We are bullish about its monetization prospects, given: 1) its great efficacy and leading progress at home; 2) Keymed’s active efforts to build sales teams; 3) the booming market of autoimmune skin diseases. Besides, we expect approval for CRSwNP/SAR by early 2025, which should boost sales. And we see rosy prospects for its early-stage pipelines, as CM313 could achieve POC for SLE (right after ITP), and the Phase III trial for CMG901 is advancing globally. We estimate Keymed’s 2024/2025/2026 EPS at RMB(3.02)/(3.26)/(1.57); our DCF-based target price is HKD58.76 (WACC: 11.4%; terminal growth: 2.5%). BUY.

關注同花順財經（ths518），獲取更多機會

0人

+1
  • 黑芝麻
  • 歐菲光
  • 君正集團
  • 晶方科技
  • 有研新材
  • 英洛華
  • 供銷大集
  • 天汽模
    • 代碼|股票名稱 最新 漲跌幅